Sustained response with ixekizumab treatment of moderate-to-severe psoriasis with scalp involvement: results from three phase 3 trials (UNCOVER-1, UNCOVER-2, UNCOVER-3)

201655 citationsJournal Articlegreen Open Access

Authors

Kristian Reich · Dermatologikum Hamburg

Craig L. Leonardi · Saint Louis University

Mark Lebwohl · Icahn School of Medicine at Mount Sinai

Francisco A. Kerdel · Florida Academic Dermatology Center

Yukari Okubo · Tokyo Medical University

Ricardo Romiti · Hospital das Clínicas da Faculdade de Medicina da Universidade de São Paulo

Orin M. Goldblum

Abstract

Ixekizumab was efficacious in treating scalp psoriasis in patients with moderate-to-severe psoriasis, with most patients achieving complete or near-complete resolution of scalp psoriasis and maintaining this response over 60 weeks.

Topics & Keywords

Psoriasis: Treatment and Pathogenesis Fibromyalgia and Chronic Fatigue Syndrome Research

UN Sustainable Development Goals

Good health and well-being

Publication Details

Published in: Journal of Dermatological Treatment

Volume 28, Issue 4, pp. 282-287

DOI: 10.1080/09546634.2016.1249820

Field-Weighted Citation Impact: 3.09